Lung Cancer

Durvalumab improved progression-free survival in unresectable NSCLC patients without progression post-chemoradiotherapy, reducing disease progression risk by 25% compared to placebo.

Pembrolizumab plus chemotherapy significantly improved 4-year OS and EFS in resectable early-stage NSCLC compared to chemotherapy alone.

Zongertinib achieved a 71% objective response rate and 93% disease control rate in patients with HER2-mutant NSCLC at a dose of 120 mg.

Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) was approved by the FDA for subcutaneous injection across approved solid tumor indications for nivolumab (Opdivo).

APPs provide an in-depth look at amivantamab plus lazertinib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer.

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small cell lung cancer.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer.

Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma (PDAC) harboring an NRG1 gene fusion.

Based on findings from a phase 2 expansion cohort, the FDA granted breakthrough therapy designation to sacituzumab tirumotecan for use in select patients with EGFR+ non–small cell lung cancer.

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer survival; however, rates have improved in the last 5 years regardless.

Subcutaneous pembrolizumab plus chemotherapy was noninferior to IV pembrolizumab plus chemotherapy in treatment-naïve non-small cell lung cancer.

The FDA received a biologics license application for datopotamab deruxtecan for previously treated EGFR-mutant non-small cell lung cancer.

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

Nurse navigators and APPs are key members of the multidisciplinary team who can lead and implement QI efforts to ensure timely and effective biomarker testing for patients with early-stage NSCLC.

The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of zenocutuzumab for NRG1-positive lung and pancreatic cancer.

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer treated with pralsetinib.

Here’s a roundup of FDA approvals in the oncology space from October 2024.

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Patients with extensive-stage small cell lung cancer tended to have better PFS and OS with complete consolidative radiotherapy compared to incomplete consolidative radiotherapy.

The addition of lurbinectedin to atezolizumab improved OS and PFS in patients with extensive-stage small cell lung cancer.

The staging of small cell lung cancer significantly impacts treatment plans and potential side effects.

A supplemental biologics license application was submitted for telisotuzumab vedotin for the treatment of metastatic EGFR wild-type nonsquamous non–small cell lung cancer.

The FDA approved neoadjuvant nivolumab plus chemo, followed by adjuvant nivolumab for non-small cell lung cancer without EGFR mutations or ALK rearrangements.

The FDA approved osimertinib for locally advanced, unresectable stage III EGFR-mutated non-small cell lung cancer.

Belrestotug plus dostarlimab-gxly improved ORR in patients with previously untreated, unresectable, locally advanced or metastatic, PD-L1–high NSCLC.

Adagrasib outperformed docetaxel in patients with KRAS G12C-mutated non–small cell lung cancer, regardless of baseline brain metastases.

The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.

The FDA approved pembrolizumab plus pemetrexted and platinum chemotherapy for advanced or metastatic malignant pleural mesothelioma.

Zipalertinib was safe and effective for heavily pretreated patients NSCLC harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell lung cancer after disease progression on osimertinib.